3 completed, 3 terminated. 5 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Terminated 2 |
| Phase 3 | 3 | Terminated 2, Completed 1 |
Follow zanolimumab: new trials by email Literature Review of zanolimumab trials Research Report on zanolimumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer Zanolimumab, Aldesleukin - Metastatic Melanoma, Metastatic Renal Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 9 | 2010-06-01 | 2015-10-28 |
| HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma HuMax-CD4 - T Cell Lymphoma | Phase 2 / Phase 3 | Completed | Emergent BioSolutions | 21 | 2005-08-01 | 2024-03-18 |
| Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome HuMax-CD4 (zanolimumab) - Mycosis Fungoides, Sezary Syndrome | Phase 3 | Terminated | Emergent Product Development Seattle LLC | 76 | 2005-07-01 | 2012-07-26 |
| Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin. HuMax-CD4 - Cutaneous T-Cell Lymphoma | Phase 2 | Completed | Genmab | 22 | 2003-05-27 | 2023-04-28 |
| Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin. HuMax-CD4 - Cutaneous T-Cell Lymphoma | Phase 2 | Completed | Genmab | 25 | 2003-04-30 | 2023-05-18 |
| Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker HuMax-CD4, Placebo, Humax-CD4 - Rheumatoid Arthritis | Phase 2 / Phase 3 | Terminated | Genmab | 83 | 2002-03-04 | 2023-04-28 |
Lymphoma, T-Cell, Cutaneous (3) · Mycosis Fungoides (3) · Sezary Syndrome (3) · Lymphoma (2) · Skin Neoplasms (2) · Arthritis, Rheumatoid (1) · Kidney Neoplasms (1) · Lymphoma, T-Cell (1) · Melanoma (1)
Genmab (3) · Emergent BioSolutions (1) · Emergent Product Development Seattle LLC (1) · National Cancer Institute (NCI) (1)
United States (5) · Germany (2) · Canada (1) · France (1) · Italy (1) · Spain (1) · Sweden (1) · United Kingdom (1)
Abhay Patki, PhD (1) · David S Schrump, M.D. (1)